国际妇产科学杂志

国际妇产科学杂志 ›› 2012, Vol. 39 ›› Issue (2): 166-169.

• 综述 • 上一篇    下一篇

CPI-17对平滑肌细胞的调节作用及其机制

周志梅,颜建英   

  1. 350004 福州,福建医科大学协和临床医学院(周志梅);福建医科大学协和临床医学院,福建省妇幼保健院(颜建英)
  • 收稿日期:1900-01-01 修回日期:1900-01-01 出版日期:2012-04-15 发布日期:2012-04-15
  • 通讯作者: 颜建英

Regulatory Effects of CPI-17 on Smooth Muscle and Its Mechanism

ZHOU Zhi-mei，YAN Jian-ying   

  1. Union Clinical Medical College of Fujian Medical University，Fuzhou 350004，China（ZHOU Zhi-mei）；Union Clinical Medical College，Fujian Maternity and Child Health Hospital，Fuzhou 350001，China（YAN Jian-ying）
  • Received:1900-01-01 Revised:1900-01-01 Published:2012-04-15 Online:2012-04-15
  • Contact: YAN Jian-ying

PDF (PC)

4886

摘要： 协同调控收缩是平滑肌的关键属性，其收缩功能正常，有助于维持机体整体健康；如发生功能失调，会增加疾病发病率和病死率。蛋白激酶C加强的磷酸酶抑制剂17（protein kinase C-potentiated phosphatase inhibitor of 17 ku，CPI-17）是磷酸化依赖的肌球蛋白轻链磷酸酶（myosin light chain phosphatase，MLCP）抑制蛋白，其可增加肌球蛋白轻链（20 ku myosin light chain，MLC20）磷酸化水平，增强平滑肌收缩。CPI-17功能受多种蛋白激酶和磷酸酶的调节。近年研究发现，在病理生理条件下，其表达和活性上调或下降与子宫、血管、气管、胃肠道等多种平滑肌功能密切相关。针对CPI-17对平滑肌细胞的调节作用及机制的深入研究有助于进一步阐明平滑肌功能障碍相关疾病及其功能失调的发病机制，并为其临床治疗提供新思路。

关键词: 蛋白质磷酸酶2, 肌球蛋白轻链磷酸酶, 肌细胞, 平滑肌, 钙调蛋白结合蛋白质类, CPI-17

Abstract: The coordinated regulation of contraction is a key property of smooth muscle，Proper function contributes to general health，but dysfunction is associated with morbidity and mortality.CPI-17（protein kinase C-potentiated phosphatase inhibitor of 17 ku）is a phosphorylation-dependent myosin phosphatase inhibitory protein，increases the phosphorylation level of 20 ku myosin light chain and enhances smooth muscle contraction.Multiple kinases and phosphateses are involved in regulating CPI-17 phosphorylation.Recent evidences show that up-and down-regulation of CPI-17 occurs under pathophysiological conditions，resulting in abnormal contraction of various smooth muscle，such as myometrium，blood vessel，trachea，gastrointestinal tract.Further studies on regulatory mechanism of CPI-17 on smooth muscle will be useful to elucidate the pathogenesis of many diseases/disorders associated with smooth muscle dysfunction and provide a new idea for the clinical treatment.

Key words: Protein phosphatase 2, Myosin-light-chain phosphatase, Myocytes, smooth muscle, Calmodulin-binding proteins, CPI-17